Both human and murine ARF proteins have been recently reported to impair rRNA maturation and ribosomes biogenesis through a p53-independent pathway. A specific interaction has been established between 5.8S rRNA and the murine p19 ARF specie. We report here, by use of both in vitro and ChIP-RNA assays, the absence of any interaction between the human p14 ARF and the homologous 5.8S rRNA. Our data are not consistent with the involvement of a 5.8S-p14
; 5.8S; ChIP-RNA The ARF tumor suppressor (p19 ARF in mouse or p14 ARF in human) regulates cell cycle by tightly controlling the G1/S restriction point through the so-called ARFMdm2-p53 pathway and also the G2/M restriction point (Sherr, 2001 ). More recently, several experimental evidence unequivocally established that ARF was able to inhibit cell proliferation independently of p53 (Carnero et al., 2000; Weber et al., 2000; Eymin et al., 2001 Eymin et al., , 2003 ). An attractive model, to explain the p53-independent antiproliferative effects of ARF, recently emerged from data reporting the ability of p19 ARF and p14 ARF to retard preribosomal RNA processing (Itahana et al., 2003; Sugimoto et al., 2003) . ARF was shown to interact with B23/Nucleophosmin, a major protein component of the nucleolus involved in the maturation of 28S rRNA. The p14 ARF /B23 interaction results in polyubiquitination and subsequent degradation of B23, leading to preribosomal RNA processing inhibition and cell death induction (Savkur and Olson, 1998; Itahana et al., 2003; Bertwistle et al., 2004) .
A specific association between p19 ARF and 5.8S rRNA, whose functional significance still remain unclear, could participate to this function (Sugimoto et al., 2003) . In this context, p14
ARF has been reported to rapidly translocate from the nucleolus to the nucleoplasm following treatment of the cells with RNAse A digestion or after cell incubation with low doses of actinomycin D (Lindstro¨m et al., 2000) , suggesting the existence of a physical interaction between ARF and rRNAs. To address more specifically this point, we performed RNAse A treatment on human 293 cells previously fixed with formaldehyde, to covalently bind nucleic acids and their associated proteins. Following elimination of the so-called soluble p14 ARF fraction by sequential washes, and reversion of the formaldehyde crosslinking, supernatants were recovered and analysed for the detection of p14 ARF by Western blot (Figure 1 ). The fraction of p14 ARF tightly associated with nuclear matrix (Ayrault et al., 2004) was recovered from cell pellets and constitute the positive control. RNAse A treatment appeared to release high amounts of RNAse sensitive p14 ARF protein arguing in favour of a direct or indirect association between p14 ARF with some cellular, potentially nucleolar RNAs.
Altogether, these results suggest an inhibitory function of ARF in a p53-independent context, involving p19 ARF for the regulation of rRNA maturation and ribosomes processing (Sugimoto et al., 2003) , and p14 ARF for the control of both rRNA transcription (Ayrault et al., 2004) and rRNA maturation (Itahana et al., 2003) .
A growing body of publications accredits the notion that murine and human ARF proteins present a number of structural differences, suggesting that their functional identity might be achieved through different molecular mechanisms (Quelle et al., 1995; Serrano et al., 1996; Wadhwa et al., 2002) . To clarify whether p14 ARF could interact with human 5.8S rRNA to negatively regulate rRNA processing, as p19 ARF potentially does, we looked for the presence of 5.8S rRNA-p14 ARF complexes through both in vitro as well in vivo approaches.
Murine p19
ARF directly interacts with mouse 5.8S rRNA whereas no interaction between human p14 ARF and 5.8S rRNA can be detected in vitro qPCR was performed once certified the quality of rRNAs and cDNAs at all steps, results are summarized in Figure 3 . Figure 3a , plot 2 clearly shows that high amounts of 5.8S murine rRNA were present in the immune complex recovered by anti-HA antibody, thus confirming the 5.8S RNA/p19 ARF interaction reported elsewhere (Sugimoto et al., 2003) . In contrast, no such interaction was detected between p14 ARF and human 5.8S RNA as no significant difference was repeatedly observed in the rRNA levels present in complexes recovered in the absence or the presence of anti-p14 . Sequential washes were performed to release the soluble fraction of the protein, then cells were separated in two fractions and incubated for 30 min at 371C in the presence or absence of 50 mg/ml RNAse A. Supernatants were recovered for subsequent analysis. Upon crosslinking reversion, equal amounts of each samples were analysed by Western blotting. Protein immunodetection was performed using the anti-p14 ARF polyclonal C-18 antibody (Santa-Cruz), and visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham). The weak signals in the two first lanes correspond to the unbound soluble protein fraction. Upon RNAse A treatment, a large amount of protein was released (lane 4, þ RNAse A), whereas no signal could be detected in the control (lane 3, ÀRNAse A). Lane 5: pellets recovered after RNAse treatment still contain p14 ARF tightly associated with nuclear matrix and correspond to p14 ARF positive control As a whole, these data confirmed those that showed the interaction of p19 ARF with 5.8S RNA (Sugimoto et al., 2003) . Furthermore, the fact that rRNA was recovered in vitro in the immunoprecipitates argued in favor of a direct interaction. In contrast, our data did not support the notion of any direct interaction of p14 ARF with human 5.8S rRNA.
Isolation of RNA/protein complexes in vivo: p14 ARF is not associated with 5S or 5.8S human rRNA in 293 cells
The above data were not entirely conclusive as they did not explore the possibility that p14 ARF might be associated with 5.8S RNA through indirect interaction. To address this question we developed a ChIP-RNA assay to detect in vivo rRNA in immune complexes recovered from cells expressing p14 ARF . At first, cell lysates were prepared from cells previously crosslinked and sonicated as described (Ayrault et al., 2004) , then immunoprecipitated with the anti-p14 ARF serum. Resulting complexes were analysed by Western blot. As expected, the ARF protein was detected in the immunoprecipitated extracts but not in the control samples without antibody, thus assessing the quality of our antibody for ChIP experiments (Figure 4a ). Next, RNAs isolated from immune complexes were reverse transcribed and amplified with different primers: GAPDH and Mdm2 genomic controls, on the one hand (Figure 4b) , and 5.8S and 5S rDNA, on the other hand (Figure 4c ). Three independent experiments were performed in parallel on IP supernatants and on immunoprecipitation complexes with and without antibody. PCR amplification of the 5.8S and 5S rRNAs in IP supernatants (input), but not in the immune complexes, confirmed the absence of any interaction between p14 ARF and 5.8S or 5S rRNA in human cells. Importantly, the absence of DNA in our samples was verified, to avoid the detection of any amplification signal corresponding to genomic rDNA instead of rRNAs, due to the high degree of conservation between these sequences (Figure 4b) . In vivo experiments are in accordance with in vitro results, as they confirm the absence of interaction between 5.8S rRNA and the human ARF protein, and they demonstrate that 5S rRNA does not interact either.
To resume, previously published data, while they established the existence of an interaction between p19 ARF and the murine 5.8S rRNA, did not provide any information about the nature of this association (Sugimoto et al., 2003; Bertwistle et al., 2004) . Our data indicate that this interaction is direct, a result that is consistent with the implication of the complex in ribosome biogenesis. In contrast, the same experimental approach failed to characterize any interaction between p14 ARF and the human 5.8S rRNA. Possibility of a degradation of 5.8S rRNA and/or p14 ARF protein in the course of the experiments was excluded by appropriate controls that assessed the integrity of the two partners. Furthermore, since genomic rRNA sequences are highly conserved among animal species, we also verified that the amplified rRNA sequence did not correspond to that , 1997) . rRNAs were recovered from immune complexes, reverse transcribed and subsequent cDNAs were amplified by qPCR with corresponding 5.8S primers. Accumulation of the specific qPCR products was detected real-time as an increase in fluorescence. Observed fluorescence was plotted against cycle number to determine Ct values (the cycle number at which logarithmic PCR plots cross a calculated threshold line). Ct were reported on the linear regression curve previously obtained, in order to quantify the corresponding copy number. Negative control was performed, on lysates from mock-infected Sf9 cells, mixed with 5.8S rRNA. Ratios were calculated as follows: Plot 2 ¼ relative copy number for (HA-p19 ARF þ murine 5.8S rRNA) mix with or without Ab/relative copy number for (AcNPV þ murine 5.8S rRNA) mix with or without Ab. Plot 3 ¼ relative copy number for (p14 ARF þ human 5.8S rRNA) mix with or without Ab/relative copy number for (AcNPV þ human 5.8S rRNA) mix with or without Ab. Plot 1: absence of interaction corresponds to a ratio ¼ 1, as Ct þ Ab/ÀAb from negative control are identical. (b) Semiquantitative PCR analysis. cDNAs were prepared as above and amplified with 5.8S PCR primers. Upon migration onto 3% agarose gel, amplification signal intensity was estimated from scanning measurements using Scan Image b4.02 software. Plots correspond to the following ratio: cDNA intensity from (ARF þ 5.8S rRNA) mix with or without antibody/cDNA intensity from (AcNPV þ 5.8S rRNA) mix with or without antibody, in mouse (plot 5) and human (plot 6). Plot 4: Absence of interaction corresponds to a ratio ¼ 1. Sf9 cell infection and immunoprecipitation success was checked by Western blotting. Integrity of rRNAs was controlled by RT-PCR after IP experiment. Endogene 5.8S rRNA was not detected from AcNPV lysate (Figure 2) Analysis of the interaction between 5.8S rRNA and ARF L Andrique et al of Sf9 cell endogenous rRNA. As a whole, these controls validated the absence of interaction between p14 ARF and 5.8S or 5S human rRNAs, therefore establishing different behaviors for p19 ARF and p14 ARF . At first, these data seem to contradict those where we showed the release of part of p14 ARF in the supernatant upon RNAse A treatment (Figure 1) . Indeed, p14 ARF has previously been shown to translocate from the nucleolus to the nucleoplasm after RNAse A treatment on adherent cells. In addition, treatment with low doses of actinomycin D also resulted in a shift of most of p14 ARF in the nucleoplasm (Lindstro¨m et al., 2000) . Taken together, these data suggest that p14 ARF nucleolar localization may be dependent on the presence of rRNA or ongoing transcription of rRNA, but they are not informative on the nature of the protein-RNA interaction as RNAse A may disrupt a ribonucleoprotein complex and release p14 ARF . Alternatively, the release may reflect a direct association between p14 ARF and RNA.
In (Itahana et al., 2003) . In both cases, this association is assumed to be a prerequisite for the action of ARF to occur. To reconcile our own data with this hypothesis, we are led to postulate the existence of two different pathways to achieve the same function through different partners in the two animal species (Wadhwa et al., 2002 and unpublished personal data) .
We recently reported the existence of a specific in vivo interaction between p14 ARF and the rRNA gene promoter, suggesting that the protein could regulate the transcription of pre-rRNA (Ayrault et al., 2004) . Our results suggest that, at least for the human species, the ARF protein may interfere with ribosomes biogenesis at different levels. If p14 ARF can be assumed to regulate both transcription (Ayrault et al., 2004) and rRNA processing (Itahana et al., 2003) , current evidence indicate that p19 ARF is only involved in ribosome assembly (Sugimoto et al., 2003; Bertwistle et al., 2004) . Thus, it is tempting to speculate that, depending on the nature of signals (such as oncogenic insults), p14 ARF protein will act at the level of rRNA transcription or the level of ribosome biogenesis.
Another question deals with putative RNA targets of p14 ARF , namely rRNA and/or other nucleolar RNA species. In our hands, neither 5.8S nor 5S rRNAs were found to associate with p14 ARF . Nevertheless, Lindstro¨m experiments strongly accredit the notion of an interaction with rRNAs. One possibility is that p14 ARF may interact with immature rRNAs molecules to block or slow down their processing. If so, p14 ARF like p19 ARF can be involved in a high molecular weight complex complex (Bertwistle et al., 2004) ARF does not interact with 5.8S nor 5S human rRNA in vivo. 293 cells were crosslinked with 1% formaldehyde and lysates were sonicated as previously described (Ayrault et al., 2004 , with minor modifications). Cell lysates were immunoprecipitated with 73SA serum against p14 ARF ( þ Ab). Negative control was performed with protein A agarose beads alone (ÀAb). RNAs were extracted from recovered immune complexes ( þ Ab/ÀAb) and from immunoprecipitation supernatants (as positive controls, input). Upon reverse transcription, cDNAs were amplified, and run onto 3% agarose gel. (b) Amplifications were performed with GAPDH and Mdm2 genomic primers to ascertain the absence of any genomic contamination. Positive PCR control corresponds to amplification from 293 cells total genomic DNA. (c) As expected, 5.8S and 5S rRNAs were detected in the immunoprecipitation supernatants (left blots: IP input), whereas no signal appeared after immunoprecipitation in the presence or absence of anti-p14 ARF 73SA serum, leading to the conclusion that the human p14 ARF does not interact with small ribosomal RNAs Analysis of the interaction between 5.8S rRNA and ARF L Andrique et al
